LanceLeopoldMD

Oncology • Dresher, PA

Physician

Join to view full profile

Are you Dr. Leopold?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
You already have 74 invites waiting!
Read the latest clinical news, personalized to your specialty.

Claim this profile

Not you? Find your profile

Office
1441 Catlin Way
Dresher, PA 19025
Phone+1 610-203-9328

Fax+1 866-305-6063

Summary

Dr. Lance Leopold, MD is an oncologist in Dresher, Pennsylvania. He is currently licensed to practice medicine in Pennsylvania.

Education & Training

Temple University Hospital-Fox Chase Cancer CenterFellowship, Hematology and Medical Oncology, 1990 - 1993
Temple University HospitalResidency, Internal Medicine, 1987 - 1990
Lewis Katz School of Medicine at Temple UniversityClass of 1987

Certifications & Licensure

PA State Medical License 1989 - 2024

Clinical Trials

Phase II Safety and Efficacy Study of Single-agent AT-101 in Patients With Relapsed or Refractory B-cell Malignancies Start of enrollment: 2005 Nov 01
Completed
Phase 2
Safety and Efficacy Study of AT-101 in Combination With Docetaxel and Prednisone in Men With HRPC Start of enrollment: 2006 Feb 01
Completed
Phase 1, Phase 2
A Study of Single-Agent AT-101 in Men With Hormone Refractory Prostate Cancer Start of enrollment: 2005 Dec 01
Completed
Phase 1, Phase 2
Study of AT-101 in Combination With Topotecan in Relapsed/Refractory Small Cell Lung Cancer Start of enrollment: 2006 Nov 01
Completed
Phase 1, Phase 2
Safety & Efficacy Study of AT-101 in Combination w/ Rituximab in Previously Untreated Grade I-II Follicular Non-Hodgkin's Lymphoma Start of enrollment: 2006 Oct 01
Completed
Phase 2
A Randomized Phase 2 Study of AT-101 in Combination With Docetaxel in Relapsed/Refractory Non-Small Cell Lung Cancer Start of enrollment: 2007 Sep 01
Completed
Phase 2
An Open-label, Single-center, Phase 1/ 2 Study of Chemoradiotherapy and AT-101 in Patients With Locally Advanced Esophageal or Gastroesophageal Junction Cancer Start of enrollment: 2007 Aug 01
Terminated
Phase 1, Phase 2
A Study Comparing AT-101 in Combination With Docetaxel and Prednisone Versus Docetaxel and Prednisone in Men With Chemotherapy-Naïve Metastatic Hormone Refractory Prostate Cancer (HRPC) Start of enrollment: 2007 Oct 01
Completed
Phase 2
A Dose-escalation Study in Subjects With Advanced Malignancies Start of enrollment: 2010 Jan 01
Completed
Phase 1
A Dose-escalation Study in Subjects With Advanced Malignancies Start of enrollment: 2010 Jul 01
Completed
Phase 1
Ruxolitinib (INCB018424) in Participants With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis (PPV-MF) Start of enrollment: 2011 Jun 15
Completed
Phase 2
Study of Ruxolitinib in Colorectal Cancer Patients Start of enrollment: 2014 Mar 01
Terminated
Phase 2
Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers Start of enrollment: 2014 Jul 17
Completed
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

8 citations
Exploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or parsaclisib in advanced solid tumors: a phase...
Aung Naing, John D Powderly, John J Nemunaitis, Jason J Luke, Aaron S Mansfield
Journal for Immunotherapy of Cancer. 2022-03-01
250 citations
Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037)
Tara C. Mitchell, Omid Hamid, David Smith, Todd M. Bauer, Jeffrey S. Wasser
Journal of Clinical Oncology. 2018-09-28
203 citations
First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies.
Gregory L. Beatty, Peter J. O'Dwyer, Jason Clark, Jack G. Shi, Kevin Bowman
Clinical Cancer Research. 2017-07-01

Press Mentions

Incyte and Mirati Therapeutics Enter into Clinical Trial Collaboration and Supply Agreement to Evaluate INCB99280 and Adagrasib in Patients with KRASG12C-Mutated Solid TumorsNovember 7th, 2022
Incyte Announces Outcome of FDA Oncologic Drugs Advisory Committee (ODAC) Meeting Reviewing Retifanlimab as a Treatment for Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC)June 24th, 2021
Incyte Announces the Validation by the European Medicines Agency of Its Marketing Authorization Application for Retifanlimab as a Treatment for Patients with Squamous Cell Anal Carcinoma (SCAC)February 26th, 2021
Join now to see all